1.5.4.1Vertical

FDA & Regulatory Law

Law firms advising pharma, biotech, and device companies on FDA matters.

Market snapshot

These figures describe Healthcare & Life Sciences Law (1.5.4), the segment that FDA & Regulatory Law sits within — not FDA & Regulatory Law on its own.

FragmentationFragmentedEstimate

Practice area within Offices of Lawyers (NAICS 541110); the Census Bureau does not size law firms by practice area.

Business model & economics

Revenue model

Hourly regulatory and transactional fees

Key economics

Recurring revenue
Moderate

recurring regulatory advisory plus deal work

EBITDA margin
Partnership profit model
Capex intensity
Low

Characteristics

  • Regulation-intensive — Stark, AKS, HIPAA, FDA drive constant demand.
  • Healthcare M&A adds a steady transactional layer.
  • Specialization commands premium, defensible positioning.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Merging & acquiring law firms
  • Firms building healthcare practices
  • Alternative business structures (Arizona)

What’s driving deals

  • Healthcare consolidation driving regulatory and deal demand.
  • Firms acquiring specialized healthcare and life-sciences teams.
  • Regulatory complexity sustaining advisory volume.

Find FDA & Regulatory Law acquisition targets

Search Acquisera’s index for companies classified under FDA & Regulatory Law (1.5.4.1) and build a targeted deal pipeline.

Search companies